Powerful cancer pain drugs were given to patients with other conditions who cannot tolerate them. A program to curb the practice was run by companies that sell the drugs. By Emily Baumgaertner The ...

As set forth in one of several district court opinions,[5] Cephalon purported to own U.S. Reissue Patent No. 37,516 (“RE ‘516”) issued in 2002, which covered Cephalon’s “flagship drug,” Provigil and ...

Get unlimited access to ad-free articles and exclusive content. What: Cephalon, Inc. (CEPH) will visit the NASDAQ MarketSite in New York City's Times Square. In honor of the occasion, Kevin Buchi, ...

NEW YORK, Dec 8 (Reuters) - Cephalon Inc's experimental cancer drug Treanda appeared to be effective in patients whose non-Hodgkin's lymphoma (NHL) had progressed during or following treatment with ...

(Reuters) - Mylan NV(MYL.O) has agreed to pay $96.5 million (£77.5 million) to settle claims by drug purchasers that it delayed launching a generic version of Cephalon Inc's narcolepsy drug Provigil ...

BALTIMORE, Sept. 8 /PRNewswire/ -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), an oncology drug development company with a predictive preclinical platform aimed at accelerating the ...

Acusphere Inc. Announces Signing of a Definitive Agreement with Cephalon, Inc. Will Provide Cephalon Up to $20 Million in Financing Plus an Upfront Payment of $5M for an Exclusive Worldwide License to ...

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it had made a proposal to the Board of Directors of Cephalon, Inc. (Nasdaq: CEPH), to acquire Cephalon for ...

Cephalon, Inc. (CEPH) Q4 2008 Earnings Call February 12, 2009 5:00 PM ETExecutivesChip Merritt - VP, IRFrank Baldino - CEOLesley Russell - CMOBob Roche - ...

The FTC filed a complaint against Cephalon in U.S. District Court for the District of Columbia on February 12, 2008. [3] At the time, Cephalon marketed a brand prescription drug called Provigil ®, ...

Cephalon Inc. reacquired rights to its cancer pain product, Actiq, in 12 countries from Elan Pharma Ltd., a subsidiary of Elan Corp. plc, to the tune of $50 million in cash. Actiq is one of three ...